Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax plus IA (2+5) versus standard 3+7 induction for newly diagnosed fit AML
ChiCTR2600132721Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lisaftoclax, idarubicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Composite complete remission rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lisaftoclaxidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600132721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132721.